Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML — Poor Outcomes Despite Longer Time to Relapse

Pavan Kumar Bhamidipati, MBBS, MD, Armin Ghobadi, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Feng Gao, PhD, Peter Westervelt, MDPhD, Geoffrey L. Uy, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 4566.

https://doi.org/10.1182/blood.V130.Suppl_1.4566.4566

Published: 2017

Journal Articles

FLT3 Positivity Is a Predictor of Early Relapse Post-Transplantation — Allo-HCT Is an Ineffective Salvage Strategy in Active AML

Pavan Kumar Bhamidipati, MBBS, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Feng Gao, PhD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Amanda F. Cashen, MD, Camille N. Abboud, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 4567.

https://doi.org/10.1182/blood.V130.Suppl_1.4567.4567

Published: 2017

Journal Articles

Statin Use Is Associated with Decreased Mortality in Multiple Myeloma— a SEER Medicare Study

Shivaprasad Manjappa, MD, Mark A. Fiala, BS, Pavan Kumar Bhamidipati, MBBS, MD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Armin Ghobadi, MD, Ravi Vij, MDMBA, Tanya M. Wildes, MDMSCI

Blood (2017) 130 (Supplement 1): 1860.

https://doi.org/10.1182/blood.V130.Suppl_1.1860.1860

Published: 2017

Journal Articles

Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation

Pavan Kumar Bhamidipati, MBBS, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Ningying Wu, PhD, Ravi Vij, MDMBA, Amanda F. Cashen, MD, John F DiPersio, MD PhD, Camille N. Abboud, MD

Blood (2017) 130 (Supplement 1): 3204.

https://doi.org/10.1182/blood.V130.Suppl_1.3204.3204

Published: 2017

Journal Articles

Reduced Intensity Hematopoietic Cell Transplantation in Active Disease AML Is Associated with Leukemia Free Survival and Relapse Comparable to Myeloablative Conditioning

Se young Han, MD, Rizwan Romee, MD, Michael Slade, BA, Pavan Kumar Bhamidipati, MBBS, MD, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Ravi Vij, Yu Tao, PhD

Blood (2016) 128 (22): 3477.

https://doi.org/10.1182/blood.V128.22.3477.3477

Published: 2016

Journal Articles

Post-Transplant Outcomes in AML Patients ≥ 60 Years of Age Beyond CR1

Dhruv Bansal, MD, Pavan Kumar Bhamidipati, MBBS, MD, Natasha Catherine Edwin, MD, Michael Slade, BA, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Ravi Vij, MD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Jingxia Liu, Rizwan Romee, MD

Blood (2016) 128 (22): 4696.

https://doi.org/10.1182/blood.V128.22.4696.4696

Published: 2016

Journal Articles

T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy

Ramzi Abboud, MD, Jesse Keller, MD, Michael Slade, BA, Michael P. Rettig, PhD, Stephanie Meier, John F. DiPersio, MD PhD, Todd A Fehniger, MD PhD, Kathryn Trinkaus, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, Ravi Vij, MD, Camille N. Abboud, MD FACP, Khoan Vu, MD, Pavan Kumar Bhamidipati, MBBS,MD, Rizwan Romee, MD

Blood (2015) 126 (23): 3106.

https://doi.org/10.1182/blood.V126.23.3106.3106

Published: 2015

Journal Articles

Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation

Se young Han, MD, Pavan Kumar Bhamidipati, MBBS,MD, Khoan Vu, MD, John F Dipersio, MD PhD, Feng Gao, PhD, Iskra Pusic, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, Ravi Vij, MD, Mark A. Schroeder, MD, Camille N. Abboud, MD FACP, Keith Stockerl-Goldstein, MD, Amanda F. Cashen, MD, Todd A Fehniger, MD PhD, Rizwan Romee, MD

Blood (2015) 126 (23): 3144.

https://doi.org/10.1182/blood.V126.23.3144.3144

Published: 2015

NARROW

Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML — Poor Outcomes Despite Longer Time to Relapse

FLT3 Positivity Is a Predictor of Early Relapse Post-Transplantation — Allo-HCT Is an Ineffective Salvage Strategy in Active AML

Statin Use Is Associated with Decreased Mortality in Multiple Myeloma— a SEER Medicare Study

Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation

Reduced Intensity Hematopoietic Cell Transplantation in Active Disease AML Is Associated with Leukemia Free Survival and Relapse Comparable to Myeloablative Conditioning

Post-Transplant Outcomes in AML Patients ≥ 60 Years of Age Beyond CR1

T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy

Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only